When EQT Partners acquired Australia-based I-Med Network Radiology, the company had spent years in the hands of different creditors. The GP had to restore confidence internally and drive long-term growth
Private equity and venture capital investment activity in Pakistan remains sparse, but early movers are beginning to cut deals with a new sense of confidence as geopolitical and economic issues simmer down
China's Tencent Holdings has led a $55 million Series D round for Indian clinic management software and doctor search portal developer Practo.
TPG Capital is seeking between $4 billion and $4.5 billion for its seventh pan-Asian fund, having closed the previous vehicle at $3.3 billion in 2014 after a challenging two-year-plus process.
The Abraaj Group has invested an undisclosed sum in Islamabad Diagnostics Centre (IDC), an affordable health diagnostics provider with 20 facilities in Pakistan.
C-Bridge Capital participates in a $100 million Series B round of funding for biotechnology Ascletis alongside existing backer Goldman Sachs and a number of its LPs
Healthcare-focused PE firm C-Bridge Capital has acquired a controlling stake in Anrei Medical Device, a China-based invasive medical devices manufacturer, for $25 million.
Frontier Biotech, a China-based pharmaceutical company that works on HIV treatments, has received RMB300 million ($43 million) in Series C funding, led by Huaxin Century Investment Group.
New Century Healthcare, a Chinese pediatric hospital operator backed by CDH Investments and Boyu Capital, is planning to raise HK$1 billion ($129 million) via a Hong Kong IPO.
Israeli venture capital firm Yozma Group has agreed to invest KRW50 billion ($41.4 million) in Korean biotechnology and healthcare start-ups, starting in the first half of 2017.
Healthcare-focused PE firm C-Bridge Capital has led a Series B round of funding worth $100 million for Ascletis, a Chinese biotechnology company that specializes in treatments for liver disease.
The Everstone Group has committed $35 million to Indian nutraceuticals ingredient supplier OmniActive Health Technologies. It is the firm’s third pharmaceuticals investment in less than a year.
TA Associates has invested INR1.72 billion ($25.5 million) in listed Indian drug ingredients manufacturer Shilpa Medicare.
Morgan Stanley Private Equity Asia (MSPEA) has invested INR1.7 billion ($25 million) in ZCL Chemicals, an India-based pharmaceuticals company that focuses on niche therapeutic areas such as the central nervous system, antiretroviral treatments and controlled...
Japanese glass, ceramic and chemicals maker AGC Asahi Glass has paid JPY60 billion ($510 million) for CMC Biologics, a Denmark-based biopharmaceutical manufacturer backed by several private equity firms.
Zai Lab has carved a niche licensing pre-clinical findings from the West for development into drugs in China, but its ambitions are global. Several VCs have faith in the project
Indian clinic management software developer and doctor search portal Practo, which is supported by several VC investors, has acquired US-based analytics firm Enlightiks.
Claris Lifesciences, an Indian drug maker with several PE backers, has agreed to exit its injectables division to US-based generic pharmaceutical developer Baxter International.
OneVentures, Brandon Capital and BioScience Managers have been selected to manage the Australian government’s A$500 million ($375 million) Biomedical Translation Fund (BTF).
Samara Capital has agreed to invest up to $25 million for a significant stake in Indian medical device manufacturer Sahajanand Medical Technologies (SMT).
India Value Fund Advisors (IVFA) has made a partial exit from India-listed pharmaceuticals company Syngene International, selling an approximately 1.6% holding for INR1.9 billion ($27.7 million).
Europe-Asia cross-border focused PE firm Mandarin Capital Partners has committed EUR16.4 million ($17.7 million) for a majority stake in Italian pharmaceutical manufacturer Mipharm.
Eight Roads Ventures has led a $12 million Series B round for India-based medical diagnostics services provider Core Diagnostics.
Novogene Technology, a Beijing-headquartered genomic services provider, has raised a $75 million Series B round from Chinese investors including CMB International, SDIC Innovation Investment and Shanghai Sigma Square Capital.